Skip to main content

Advertisement

SpringerLink
Log in

Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas

  • Clinical-patient studies
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Purpose To evaluate outcome after fractionated stereotactic radiotherapy (FSRT) and concomitant daily temozolomide (TMZ) in patients with recurrent gliomas. Materials and Methods Twenty-five patients with recurrent or progressive gliomas were treated with FSRT in combination with TMZ at the Department of Radiation Oncology, University of Heidelberg. Histologic classification at primary diagnosis included low-grade astrocytoma in 7 patients (28%), grade III gliomas in 10 patients (40%) and glioblastoma in 8 patients (32%). All patients had undergone at least one neurosurgical resection, which was complete in 5 patients (20%), subtotal in 13 patients (52%) and a biopsy only in 7 patients (28%). Nineteen patients (76%) had undergone neurosurgical resection for tumor recurrence. All patients had received radiation therapy with a median dose of 60 Gy. The median time interval between primary RT and re-irradiation was 36 months. Using FSRT, we applied a median total dose of 36 Gy in a median fractionation of 5 × 2 Gy/week. Chemotherapy with TMZ was applied in a median dose of 50 mg/m2. Results Median overall survival was 59 months. Median survival from re-irradiation was 8 months. Actuarial survival rates at 6 and 12 months were 81% and 25%. Median PFS was 5 months; actuarial PFS rates at 6 and 12 months were 48% and 16%. Treatment could be completed in all patients as scheduled without interruptions >3 days. No severe treatment-related side effects could be observed. Conclusion Re-irradiation and TMZ is safe and effective in a subgroup of patients with recurrent gliomas. Further evaluation of radiochemotherapy regimens for recurrent or progressive gliomas is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Dirks P, Bernstein M, Muller PJ, Tucker WS (1993) The value of reoperation for recurrent glioblastoma. Can J Surg 36:271–275

    PubMed  CAS  Google Scholar 

  2. Harsh GR, Levin VA, Gutin PH, Seager M, Silver P, Wilson CB (1987) Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21:615–621

    Article  PubMed  Google Scholar 

  3. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762–2771

    PubMed  CAS  Google Scholar 

  4. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357–3361

    Article  PubMed  CAS  Google Scholar 

  5. Bauman GS, Sneed PK, Wara WM, Stalpers LJ, Chang SM, McDermott MW et al (1996) Reirradiation of primary CNS tumors. Int J Radiat Oncol Biol Phys 36:433–441

    PubMed  CAS  Google Scholar 

  6. Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23:8863–8869

    Article  PubMed  Google Scholar 

  7. Combs SE, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D (2005) Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer 104:2168–2173

    Article  PubMed  Google Scholar 

  8. Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  9. Combs SE, Gutwein S, Schulz-Ertner D, van Kampen M, Thilmann C, Edler L et al (2005) Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol 181:372–377

    Article  PubMed  Google Scholar 

  10. Arcicasa M, Roncadin M, Bidoli E, Dedkov A, Gigante M, Trovo MG (1999) Reirradiation and lomustine in patients with relapsed high-grade gliomas. Int J Radiat Oncol Biol Phys 43:789–793

    PubMed  CAS  Google Scholar 

  11. Wurm RE, Kuczer DA, Schlenger L, Matnjani G, Scheffler D, Cosgrove VP et al (2006) Hypofractionated stereotactic radiotherapy combined with topotecan in recurrent malignant glioma. Int J Radiat Oncol Biol Phys 66:S26–S32

    Google Scholar 

  12. Glass J, Silverman CL, Axelrod R, Corn BW, Andrews DW (1997) Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma. Am J Clin Oncol 20:226–229

    Article  PubMed  CAS  Google Scholar 

  13. Lederman G, Wronski M, Arbit E, Odaimi M, Wertheim S, Lombardi E et al (2000) Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 23:155–159

    Article  PubMed  CAS  Google Scholar 

  14. Menke M, Hirschfeld F, Mack T, Pastyr O, Sturm V, Schlegel W (1994) Photogrammetric accuracy measurements of head holder systems used for fractionated radiotherapy. Int J Radiat Oncol Biol Phys 29:1147–1155

    PubMed  CAS  Google Scholar 

  15. Schulz-Ertner D, Frank C, Herfarth KK, Rhein B, Wannenmacher M, Debus J (2002) Fractionated stereotactic radiotherapy for craniopharyngiomas. Int J Radiat Oncol Biol Phys 54:1114–1120

    Article  PubMed  Google Scholar 

  16. Clark TG, Bradburn MJ, Love SB, Altman DG (2003) Survival analysis part IV: further concepts and methods in survival analysis. Br J Cancer 89:781–786

    Article  PubMed  CAS  Google Scholar 

  17. Clark TG, Bradburn MJ, Love SB, Altman DG (2003) Survival analysis part I: basic concepts and first analyses. Br J Cancer 89:232–238

    Article  PubMed  CAS  Google Scholar 

  18. Park I, Tamai G, Lee MC, Chuang CF, Chang SM, Berger MS et al. (2007) Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. Int J Radiat Oncol Biol Phys

  19. Sneed PK, Gutin PH, Larson DA, Malec MK, Phillips TL, Prados MD et al (1994) Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 29:719–727

    PubMed  CAS  Google Scholar 

  20. Brandes AA, Fiorentino MV (1996) The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Invest 14:551–559

    Article  PubMed  CAS  Google Scholar 

  21. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593

    Article  PubMed  CAS  Google Scholar 

  22. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B et al (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563–2569

    Article  PubMed  CAS  Google Scholar 

  23. Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE (2005) Salvage temozolomide for prior temozolomide responders. Cancer 104:2473–2476

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

SEC, DSE and JD received research grants from Schering-Plough. SEC served on advisory boards and received speakers’ honoraria from Schering-Plough.

Author information

Authors and Affiliations

  1. Neuro-Radiation Oncology Research Group, Department of Radiation Oncology, University of Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany

    Stephanie E. Combs, Marc Bischof, Thomas Welzel, Holger Hof, Susanne Oertel, Jürgen Debus & Daniela Schulz-Ertner

Authors
  1. Stephanie E. Combs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc Bischof
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Welzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Holger Hof
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Susanne Oertel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jürgen Debus
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Daniela Schulz-Ertner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephanie E. Combs.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Combs, S.E., Bischof, M., Welzel, T. et al. Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J Neurooncol 89, 205–210 (2008). https://doi.org/10.1007/s11060-008-9607-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-008-9607-4

Keywords

Search

Navigation